Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy

Hung Chang Liu, Shih Kai Hung, Charn Jer Huang, Chung Chu Chen, Ming Jen Chen, Chun Chao Chang, Cheng Jeng Tai, Chi Yuan Tzen, Li Hua Lu, Yu Jen Chen

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aim: To compare the efficacy and toxicity of a three-step combination therapy with post-operative radiation alone for locally advanced esophageal cancer. Methods: Patients with T3-4 and N0-1 esophageal carcinoma from a number of institutions were non-randomly, prospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. The patients were then assigned into one of two treatment groups based on treatment consisting of either post-operative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m2 followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m2 and 5-fluorouracil 1 000 mg/m2 for five consecutive days), or, post-operative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Primary end-point of this study was to assess the per-protocol patients' improvement of overall survival benefit. Secondary end-point was designed to evaluate both the per-protocol and intent-to-treat patients' outcome of survival. Results: A total of 60 patients (n = 30 per group) were enrolled in this study. The two groups were generally comparable for demographic characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better overall survival (30.9 mo vs 20.7 mo; 95% CI, 27.5-36.4 vs 15.2-26.1) and 3-year survival (70.0% vs 33.7%; P = 0.003). Low histological grade of tumor (P

Original languageEnglish
Pages (from-to)5367-5372
Number of pages6
JournalWorld Journal of Gastroenterology
Volume11
Issue number34
Publication statusPublished - Sep 14 2005

Fingerprint

Esophagectomy
Chemoradiotherapy
Adjuvant Chemotherapy
Esophageal Neoplasms
Cisplatin
Survival
Radiation
Fluorouracil
Radiotherapy
Therapeutics
Demography
Carcinoma
Neoplasms

Keywords

  • Cisplatin
  • Concurrent chemoradiotherapy
  • Curative esophagectomy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Liu, H. C., Hung, S. K., Huang, C. J., Chen, C. C., Chen, M. J., Chang, C. C., ... Chen, Y. J. (2005). Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World Journal of Gastroenterology, 11(34), 5367-5372.

Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. / Liu, Hung Chang; Hung, Shih Kai; Huang, Charn Jer; Chen, Chung Chu; Chen, Ming Jen; Chang, Chun Chao; Tai, Cheng Jeng; Tzen, Chi Yuan; Lu, Li Hua; Chen, Yu Jen.

In: World Journal of Gastroenterology, Vol. 11, No. 34, 14.09.2005, p. 5367-5372.

Research output: Contribution to journalArticle

Liu, HC, Hung, SK, Huang, CJ, Chen, CC, Chen, MJ, Chang, CC, Tai, CJ, Tzen, CY, Lu, LH & Chen, YJ 2005, 'Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy', World Journal of Gastroenterology, vol. 11, no. 34, pp. 5367-5372.
Liu, Hung Chang ; Hung, Shih Kai ; Huang, Charn Jer ; Chen, Chung Chu ; Chen, Ming Jen ; Chang, Chun Chao ; Tai, Cheng Jeng ; Tzen, Chi Yuan ; Lu, Li Hua ; Chen, Yu Jen. / Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. In: World Journal of Gastroenterology. 2005 ; Vol. 11, No. 34. pp. 5367-5372.
@article{045452dd7c0b4784bf041d3ea3d2454f,
title = "Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy",
abstract = "Aim: To compare the efficacy and toxicity of a three-step combination therapy with post-operative radiation alone for locally advanced esophageal cancer. Methods: Patients with T3-4 and N0-1 esophageal carcinoma from a number of institutions were non-randomly, prospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. The patients were then assigned into one of two treatment groups based on treatment consisting of either post-operative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m2 followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m2 and 5-fluorouracil 1 000 mg/m2 for five consecutive days), or, post-operative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Primary end-point of this study was to assess the per-protocol patients' improvement of overall survival benefit. Secondary end-point was designed to evaluate both the per-protocol and intent-to-treat patients' outcome of survival. Results: A total of 60 patients (n = 30 per group) were enrolled in this study. The two groups were generally comparable for demographic characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better overall survival (30.9 mo vs 20.7 mo; 95{\%} CI, 27.5-36.4 vs 15.2-26.1) and 3-year survival (70.0{\%} vs 33.7{\%}; P = 0.003). Low histological grade of tumor (P",
keywords = "Cisplatin, Concurrent chemoradiotherapy, Curative esophagectomy",
author = "Liu, {Hung Chang} and Hung, {Shih Kai} and Huang, {Charn Jer} and Chen, {Chung Chu} and Chen, {Ming Jen} and Chang, {Chun Chao} and Tai, {Cheng Jeng} and Tzen, {Chi Yuan} and Lu, {Li Hua} and Chen, {Yu Jen}",
year = "2005",
month = "9",
day = "14",
language = "English",
volume = "11",
pages = "5367--5372",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "34",

}

TY - JOUR

T1 - Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy

AU - Liu, Hung Chang

AU - Hung, Shih Kai

AU - Huang, Charn Jer

AU - Chen, Chung Chu

AU - Chen, Ming Jen

AU - Chang, Chun Chao

AU - Tai, Cheng Jeng

AU - Tzen, Chi Yuan

AU - Lu, Li Hua

AU - Chen, Yu Jen

PY - 2005/9/14

Y1 - 2005/9/14

N2 - Aim: To compare the efficacy and toxicity of a three-step combination therapy with post-operative radiation alone for locally advanced esophageal cancer. Methods: Patients with T3-4 and N0-1 esophageal carcinoma from a number of institutions were non-randomly, prospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. The patients were then assigned into one of two treatment groups based on treatment consisting of either post-operative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m2 followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m2 and 5-fluorouracil 1 000 mg/m2 for five consecutive days), or, post-operative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Primary end-point of this study was to assess the per-protocol patients' improvement of overall survival benefit. Secondary end-point was designed to evaluate both the per-protocol and intent-to-treat patients' outcome of survival. Results: A total of 60 patients (n = 30 per group) were enrolled in this study. The two groups were generally comparable for demographic characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better overall survival (30.9 mo vs 20.7 mo; 95% CI, 27.5-36.4 vs 15.2-26.1) and 3-year survival (70.0% vs 33.7%; P = 0.003). Low histological grade of tumor (P

AB - Aim: To compare the efficacy and toxicity of a three-step combination therapy with post-operative radiation alone for locally advanced esophageal cancer. Methods: Patients with T3-4 and N0-1 esophageal carcinoma from a number of institutions were non-randomly, prospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. The patients were then assigned into one of two treatment groups based on treatment consisting of either post-operative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m2 followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m2 and 5-fluorouracil 1 000 mg/m2 for five consecutive days), or, post-operative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Primary end-point of this study was to assess the per-protocol patients' improvement of overall survival benefit. Secondary end-point was designed to evaluate both the per-protocol and intent-to-treat patients' outcome of survival. Results: A total of 60 patients (n = 30 per group) were enrolled in this study. The two groups were generally comparable for demographic characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better overall survival (30.9 mo vs 20.7 mo; 95% CI, 27.5-36.4 vs 15.2-26.1) and 3-year survival (70.0% vs 33.7%; P = 0.003). Low histological grade of tumor (P

KW - Cisplatin

KW - Concurrent chemoradiotherapy

KW - Curative esophagectomy

UR - http://www.scopus.com/inward/record.url?scp=26244452199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244452199&partnerID=8YFLogxK

M3 - Article

C2 - 16149148

AN - SCOPUS:26244452199

VL - 11

SP - 5367

EP - 5372

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 34

ER -